Lupin Fires Back At Novartis In Lotrel Patent Spat
Indian generics giant Lupin Ltd. filed counterclaims Monday in a suit over Lotrel, saying Novartis Corp. deceived the U.S. Patent and Trademark Office into issuing the patent to the billion-dollar hypertension...To view the full article, register now.
Already a subscriber? Click here to view full article